Renal Cell Carcinoma | Clinical

FDA Approves Adjuvant Pembrolizumab for Renal Cell Carcinoma

November 18, 2021

The FDA has approved adjuvant pembrolizumab for the treatment of renal cell carcinoma with an intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.